Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 160

1.

Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma.

Ferrarotto R, William WN Jr, Tseng JE, Marur S, Shin DM, Murphy B, Cohen EEW, Thomas CY, Willey R, Cosaert J, Harun N, Jack Lee J, Wistuba IW, Haddad RI, Glisson BS.

Oral Oncol. 2018 Jul;82:83-90. doi: 10.1016/j.oraloncology.2018.05.014. Epub 2018 May 19.

PMID:
29909907
2.

Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models.

Crossland DL, Denning WL, Ang S, Olivares S, Mi T, Switzer K, Singh H, Huls H, Gold KS, Glisson BS, Cooper LJ, Heymach JV.

Oncogene. 2018 Apr 6. doi: 10.1038/s41388-018-0187-2. [Epub ahead of print]

PMID:
29622795
3.

Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial.

Gold KA, Kies MS, William WN Jr, Johnson FM, Lee JJ, Glisson BS.

Cancer. 2018 May 15;124(10):2169-2173. doi: 10.1002/cncr.31346. Epub 2018 Mar 26.

PMID:
29579331
4.

Poly ADP-ribose polymerase-1 as a potential therapeutic target in Merkel cell carcinoma.

Ferrarotto R, Cardnell R, Su S, Diao L, Eterovic AK, Prieto V, Morrisson WH, Wang J, Kies MS, Glisson BS, Byers LA, Bell D.

Head Neck. 2018 Mar 23. doi: 10.1002/hed.25146. [Epub ahead of print]

PMID:
29570891
5.

Single Arm, Phase II Study of Cisplatin, Docetaxel, and Erlotinib in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas.

William WN Jr, Tsao AS, Feng L, Ginsberg LE, Lee JJ, Kies MS, Glisson BS, Kim ES.

Oncologist. 2018 May;23(5):526-e49. doi: 10.1634/theoncologist.2017-0661. Epub 2018 Jan 25.

6.

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2).

Aisner DL, Sholl LM, Berry LD, Rossi MR, Chen H, Fujimoto J, Moreira AL, Ramalingam SS, Villaruz LC, Otterson GA, Haura E, Politi K, Glisson B, Cetnar J, Garon EB, Schiller J, Waqar SN, Sequist LV, Brahmer J, Shyr Y, Kugler K, Wistuba II, Johnson BE, Minna JD, Kris MG, Bunn PA, Kwiatkowski DJ; LCMC2 investigators.

Clin Cancer Res. 2018 Mar 1;24(5):1038-1047. doi: 10.1158/1078-0432.CCR-17-2289. Epub 2017 Dec 7.

PMID:
29217530
7.

Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies.

Cardnell RJ, Li L, Sen T, Bara R, Tong P, Fujimoto J, Ireland AS, Guthrie MR, Bheddah S, Banerjee U, Kalu NN, Fan YH, Dylla SJ, Johnson FM, Wistuba II, Oliver TG, Heymach JV, Glisson BS, Wang J, Byers LA.

Oncotarget. 2017 Sep 1;8(43):73419-73432. doi: 10.18632/oncotarget.20621. eCollection 2017 Sep 26.

8.

Gefitinib for patients with incurable cutaneous squamous cell carcinoma: A single-arm phase II clinical trial.

William WN Jr, Feng L, Ferrarotto R, Ginsberg L, Kies M, Lippman S, Glisson B, Kim ES.

J Am Acad Dermatol. 2017 Dec;77(6):1110-1113.e2. doi: 10.1016/j.jaad.2017.07.048. Epub 2017 Sep 28.

PMID:
28964539
9.

A Randomized, Placebo-Controlled, Phase 1b/2 Study of Rilotumumab or Ganitumab in Combination With Platinum-Based Chemotherapy as First-Line Treatment for Extensive-Stage Small-Cell Lung Cancer.

Glisson B, Besse B, Dols MC, Dubey S, Schupp M, Jain R, Jiang Y, Menon H, Nackaerts K, Orlov S, Paz-Ares L, Ramlau R, Tang R, Zhang Y, Zhu M.

Clin Lung Cancer. 2017 Nov;18(6):615-625.e8. doi: 10.1016/j.cllc.2017.05.007. Epub 2017 May 10.

PMID:
28601388
10.

Outcomes for olfactory neuroblastoma treated with induction chemotherapy.

Su SY, Bell D, Ferrarotto R, Phan J, Roberts D, Kupferman ME, Frank SJ, Fuller CD, Gunn GB, Kies MS, Glisson BS, Hanna EY.

Head Neck. 2017 Aug;39(8):1671-1679. doi: 10.1002/hed.24822. Epub 2017 May 31.

PMID:
28561956
11.

CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.

Sen T, Tong P, Stewart CA, Cristea S, Valliani A, Shames DS, Redwood AB, Fan YH, Li L, Glisson BS, Minna JD, Sage J, Gibbons DL, Piwnica-Worms H, Heymach JV, Wang J, Byers LA.

Cancer Res. 2017 Jul 15;77(14):3870-3884. doi: 10.1158/0008-5472.CAN-16-3409. Epub 2017 May 10.

12.

Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.

Allison Stewart C, Tong P, Cardnell RJ, Sen T, Li L, Gay CM, Masrorpour F, Fan Y, Bara RO, Feng Y, Ru Y, Fujimoto J, Kundu ST, Post LE, Yu K, Shen Y, Glisson BS, Wistuba I, Heymach JV, Gibbons DL, Wang J, Byers LA.

Oncotarget. 2017 Apr 25;8(17):28575-28587. doi: 10.18632/oncotarget.15338.

13.

ORAL02.01: Safety and Efficacy of Single-Agent Rovalpituzumab Tesirine, a DLL3-Targeted ADC, in Recurrent or Refractory SCLC: Topic: Medical Oncology.

Bauer TM, Spigel D, Ready N, Morgensztern D, Glisson BS, Byers LA, Burris H, Robert F, Strickland DK, Pietanza MC, Govindan R, Dylla SJ, Peng S, Rudin C.

J Thorac Oncol. 2016 Nov;11(11S):S252-S253. doi: 10.1016/j.jtho.2016.09.010. Epub 2016 Oct 28. No abstract available.

14.

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study.

Rudin CM, Pietanza MC, Bauer TM, Ready N, Morgensztern D, Glisson BS, Byers LA, Johnson ML, Burris HA 3rd, Robert F, Han TH, Bheddah S, Theiss N, Watson S, Mathur D, Vennapusa B, Zayed H, Lally S, Strickland DK, Govindan R, Dylla SJ, Peng SL, Spigel DR; SCRX16-001 investigators.

Lancet Oncol. 2017 Jan;18(1):42-51. doi: 10.1016/S1470-2045(16)30565-4. Epub 2016 Dec 5.

15.

Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.

Ferrarotto R, Mitani Y, Diao L, Guijarro I, Wang J, Zweidler-McKay P, Bell D, William WN Jr, Glisson BS, Wick MJ, Kapoun AM, Patnaik A, Eckhardt G, Munster P, Faoro L, Dupont J, Lee JJ, Futreal A, El-Naggar AK, Heymach JV.

J Clin Oncol. 2017 Jan 20;35(3):352-360. doi: 10.1200/JCO.2016.67.5264. Epub 2016 Nov 21.

16.

MYB-fusions and other potential actionable targets in adenoid cystic carcinoma.

Ferrarotto R, Heymach JV, Glisson BS.

Curr Opin Oncol. 2016 May;28(3):195-200. doi: 10.1097/CCO.0000000000000280. Review.

PMID:
26974847
17.

Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus.

Liu X, Kambrick S, Fu S, Naing A, Subbiah V, Blumenschein GR, Glisson BS, Kies MS, Tsimberidou AM, Wheler JJ, Zinner RG, Hong DS, Kurzrock R, Piha-Paul SA.

Oncotarget. 2016 Apr 26;7(17):23227-38. doi: 10.18632/oncotarget.7594.

18.

Outcomes for hypopharyngeal carcinoma treated with organ-preservation therapy.

Edson MA, Garden AS, Takiar V, Glisson BS, Fuller CD, Gunn GB, Beadle BM, Morrison WH, Frank SJ, Shah SJ, Tao R, William WN, Weber RS, Rosenthal DI, Phan J.

Head Neck. 2016 Apr;38 Suppl 1:E2091-9. doi: 10.1002/hed.24387. Epub 2016 Feb 27.

PMID:
26920665
19.

Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.

Ferrarotto R, Goonatilake R, Yoo SY, Tong P, Giri U, Peng S, Minna J, Girard L, Wang Y, Wang L, Li L, Diao L, Peng DH, Gibbons DL, Glisson BS, Heymach JV, Wang J, Byers LA, Johnson FM.

Clin Cancer Res. 2016 Apr 1;22(7):1674-1686. doi: 10.1158/1078-0432.CCR-14-2890. Epub 2015 Nov 23.

20.

Prognostic value of p16 expression in Epstein-Barr virus-positive nasopharyngeal carcinomas.

Jiang W, Chamberlain PD, Garden AS, Kim BY, Ma D, Lo EJ, Bell D, Gunn GB, Fuller CD, Rosenthal DI, Beadle BM, Frank SJ, Morrison WH, El-Naggar AK, Glisson BS, Sturgis EM, Phan J.

Head Neck. 2016 Apr;38 Suppl 1:E1459-66. doi: 10.1002/hed.24258. Epub 2015 Nov 11.

21.

New Strategies in Human Papillomavirus-Related Oropharynx Cancer: Effecting Advances in Treatment for a Growing Epidemic.

Massarelli E, Ferrarotto R, Glisson BS.

Clin Cancer Res. 2015 Sep 1;21(17):3821-8. doi: 10.1158/1078-0432.CCR-14-1329. Review.

22.

Drug-induced RAF dimerization is independent of RAS mutation status and does not lead to universal MEK dependence for cell survival in head and neck cancers.

Mazumdar T, Sen B, Wang Y, Peng S, Nicholas C, Glisson BS, Myers JN, Johnson FM.

Anticancer Drugs. 2015 Sep;26(8):835-42. doi: 10.1097/CAD.0000000000000251.

23.

Small cell lung carcinoma: staging, imaging, and treatment considerations.

Carter BW, Glisson BS, Truong MT, Erasmus JJ.

Radiographics. 2014 Oct;34(6):1707-21. doi: 10.1148/rg.346140178. Review.

PMID:
25310425
24.

A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma.

Mazumdar T, Byers LA, Ng PK, Mills GB, Peng S, Diao L, Fan YH, Stemke-Hale K, Heymach JV, Myers JN, Glisson BS, Johnson FM.

Mol Cancer Ther. 2014 Nov;13(11):2738-50. doi: 10.1158/1535-7163.MCT-13-1090. Epub 2014 Sep 5.

25.

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.

Kris MG, Johnson BE, Berry LD, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Varella-Garcia M, Franklin WA, Aronson SL, Su PF, Shyr Y, Camidge DR, Sequist LV, Glisson BS, Khuri FR, Garon EB, Pao W, Rudin C, Schiller J, Haura EB, Socinski M, Shirai K, Chen H, Giaccone G, Ladanyi M, Kugler K, Minna JD, Bunn PA.

JAMA. 2014 May 21;311(19):1998-2006. doi: 10.1001/jama.2014.3741.

26.

Is there still a role for induction chemotherapy in locally advanced head and neck cancer?

Mak MP, Glisson BS.

Curr Opin Oncol. 2014 May;26(3):247-51. doi: 10.1097/CCO.0000000000000073. Review.

PMID:
24651382
27.

Phase II study of gefitinib in patients with advanced salivary gland cancers.

Jakob JA, Kies MS, Glisson BS, Kupferman ME, Liu DD, Lee JJ, El-Naggar AK, Gonzalez-Angulo AM, Blumenschein GR Jr.

Head Neck. 2015 May;37(5):644-9. doi: 10.1002/hed.23647. Epub 2015 Mar 30.

28.

Combating resistance to anti-IGFR antibody by targeting the integrin ╬▓3-Src pathway.

Shin DH, Lee HJ, Min HY, Choi SP, Lee MS, Lee JW, Johnson FM, Mehta K, Lippman SM, Glisson BS, Lee HY.

J Natl Cancer Inst. 2013 Oct 16;105(20):1558-70. doi: 10.1093/jnci/djt263. Epub 2013 Oct 3.

29.

The impact of radiographic retropharyngeal adenopathy in oropharyngeal cancer.

Gunn GB, Debnam JM, Fuller CD, Morrison WH, Frank SJ, Beadle BM, Sturgis EM, Glisson BS, Phan J, Rosenthal DI, Garden AS.

Cancer. 2013 Sep 1;119(17):3162-9. doi: 10.1002/cncr.28195. Epub 2013 Jun 3. Erratum in: Cancer. 2013 Dec 15;119(24):4368.

30.

Outcomes and patterns of care of patients with locally advanced oropharyngeal carcinoma treated in the early 21st century.

Garden AS, Kies MS, Morrison WH, Weber RS, Frank SJ, Glisson BS, Gunn GB, Beadle BM, Ang KK, Rosenthal DI, Sturgis EM.

Radiat Oncol. 2013 Jan 29;8:21. doi: 10.1186/1748-717X-8-21.

31.

Epidermal growth factor receptor inhibitors for treatment of orbital squamous cell carcinoma.

El-Sawy T, Sabichi AL, Myers JN, Kies MS, William WN, Glisson BS, Lippman S, Esmaeli B.

Arch Ophthalmol. 2012 Dec;130(12):1608-11. doi: 10.1001/archophthalmol.2012.2515. No abstract available.

PMID:
23229707
32.

Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer.

Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, Morrison W, Glisson B, Trotti A, Ridge JA, Thorstad W, Wagner H, Ensley JF, Cooper JS.

J Clin Oncol. 2013 Mar 1;31(7):845-52. doi: 10.1200/JCO.2012.43.6097. Epub 2012 Nov 26.

33.

Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways.

Raju U, Riesterer O, Wang ZQ, Molkentine DP, Molkentine JM, Johnson FM, Glisson B, Milas L, Ang KK.

Radiother Oncol. 2012 Nov;105(2):241-9. doi: 10.1016/j.radonc.2012.08.010. Epub 2012 Sep 23.

PMID:
23010482
34.

Patterns of disease recurrence following treatment of oropharyngeal cancer with intensity modulated radiation therapy.

Garden AS, Dong L, Morrison WH, Stugis EM, Glisson BS, Frank SJ, Beadle BM, Gunn GB, Schwartz DL, Kies MS, Weber RS, Ang KK, Rosenthal DI.

Int J Radiat Oncol Biol Phys. 2013 Mar 15;85(4):941-7. doi: 10.1016/j.ijrobp.2012.08.004. Epub 2012 Sep 11.

PMID:
22975604
35.

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, Giri U, Peyton M, Fan YH, Diao L, Masrorpour F, Shen L, Liu W, Duchemann B, Tumula P, Bhardwaj V, Welsh J, Weber S, Glisson BS, Kalhor N, Wistuba II, Girard L, Lippman SM, Mills GB, Coombes KR, Weinstein JN, Minna JD, Heymach JV.

Cancer Discov. 2012 Sep;2(9):798-811. doi: 10.1158/2159-8290.CD-12-0112. Epub 2012 Sep 6.

36.

An evolution in demographics, treatment, and outcomes of oropharyngeal cancer at a major cancer center: a staging system in need of repair.

Dahlstrom KR, Calzada G, Hanby JD, Garden AS, Glisson BS, Li G, Roberts DB, Weber RS, Sturgis EM.

Cancer. 2013 Jan 1;119(1):81-9. doi: 10.1002/cncr.27727. Epub 2012 Jun 26.

37.

Phase II study of accelerated high-dose radiotherapy with concurrent chemotherapy for patients with limited small-cell lung cancer: Radiation Therapy Oncology Group protocol 0239.

Komaki R, Paulus R, Ettinger DS, Videtic GM, Bradley JD, Glisson BS, Langer CJ, Sause WT, Curran WJ Jr, Choy H.

Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):e531-6. doi: 10.1016/j.ijrobp.2012.01.075. Epub 2012 May 5.

38.

Insulin-like growth factor binding protein-3 suppresses vascular endothelial growth factor expression and tumor angiogenesis in head and neck squamous cell carcinoma.

Oh SH, Kim WY, Lee OH, Kang JH, Woo JK, Kim JH, Glisson B, Lee HY.

Cancer Sci. 2012 Jul;103(7):1259-66. doi: 10.1111/j.1349-7006.2012.02301.x. Epub 2012 May 25. Erratum in: Cancer Sci. 2012 Aug;103(8):1600.

39.

Histone deacetylase inhibitors enhance the apoptotic activity of insulin-like growth factor binding protein-3 by blocking PKC-induced IGFBP-3 degradation.

Oh SH, Whang YM, Min HY, Han SH, Kang JH, Song KH, Glisson BS, Kim YH, Lee HY.

Int J Cancer. 2012 Nov 15;131(10):2253-63. doi: 10.1002/ijc.27509. Epub 2012 Mar 28.

40.

Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors.

Kim WY, Prudkin L, Feng L, Kim ES, Hennessy B, Lee JS, Lee JJ, Glisson B, Lippman SM, Wistuba II, Hong WK, Lee HY.

Cancer. 2012 Aug 15;118(16):3993-4003. doi: 10.1002/cncr.26656. Epub 2012 Feb 22. Erratum in: Cancer. 2012 Dec 15;118(24):6301.

41.

Prediction of neck dissection requirement after definitive radiotherapy for head-and-neck squamous cell carcinoma.

Thariat J, Ang KK, Allen PK, Ahamad A, Williams MD, Myers JN, El-Naggar AK, Ginsberg LE, Rosenthal DI, Glisson BS, Morrison WH, Weber RS, Garden AS.

Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):e367-74. doi: 10.1016/j.ijrobp.2011.03.062.

42.

A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck.

Lewis CM, Glisson BS, Feng L, Wan F, Tang X, Wistuba II, El-Naggar AK, Rosenthal DI, Chambers MS, Lustig RA, Weber RS.

Clin Cancer Res. 2012 Mar 1;18(5):1435-46. doi: 10.1158/1078-0432.CCR-11-1951. Epub 2012 Jan 18.

43.

Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial.

Lee NY, Zhang Q, Pfister DG, Kim J, Garden AS, Mechalakos J, Hu K, Le QT, Colevas AD, Glisson BS, Chan AT, Ang KK.

Lancet Oncol. 2012 Feb;13(2):172-80. doi: 10.1016/S1470-2045(11)70303-5. Epub 2011 Dec 15.

44.

Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody.

Shin DH, Min HY, El-Naggar AK, Lippman SM, Glisson B, Lee HY.

Mol Cancer Ther. 2011 Dec;10(12):2437-48. doi: 10.1158/1535-7163.MCT-11-0235. Epub 2011 Oct 6.

45.

Large-cell neuroendocrine carcinoma: controversies in diagnosis and treatment.

Glisson BS, Moran CA.

J Natl Compr Canc Netw. 2011 Oct;9(10):1122-9.

PMID:
21975912
46.

Novel strategies for the treatment of small-cell lung carcinoma.

William WN Jr, Glisson BS.

Nat Rev Clin Oncol. 2011 Jun 21;8(10):611-9. doi: 10.1038/nrclinonc.2011.90. Review.

PMID:
21691321
47.

Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma.

Brooks HD, Glisson BS, Bekele BN, Johnson FM, Ginsberg LE, El-Naggar A, Culotta KS, Takebe N, Wright J, Tran HT, Papadimitrakopoulou VA.

Cancer. 2011 May 15;117(10):2112-9. doi: 10.1002/cncr.25769. Epub 2010 Nov 29. Erratum in: Cancer. 2012 May 1;118(9):2560. Johnson, Faye M [added].

48.

Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial.

Gitlitz BJ, Moon J, Glisson BS, Reimers HJ, Bury MJ, Floyd JD, Schulz TK, Sundaram PK, Ho C, Gandara DR.

J Thorac Oncol. 2010 Nov;5(11):1835-40. doi: 10.1097/JTO.0b013e3181f0bd78.

49.

Extensive disease small cell lung cancer dose-response relationships: implications for resistance mechanisms.

Stewart DJ, Johnson C, Lopez A, Glisson B, Rhee JM, Bekele BN.

J Thorac Oncol. 2010 Nov;5(11):1826-34. doi: 10.1097/JTO.0b013e3181f387c7.

50.

Targeting an autocrine loop in small-cell lung cancer: irrelevant target or ineffective drug?

Glisson BS.

Clin Lung Cancer. 2010 Jul 1;11(4):222. doi: 10.3816/CLC.2010.n.027. No abstract available.

PMID:
20630822

Supplemental Content

Loading ...
Support Center